Regenxbio (RGNX) EBIAT (2016 - 2025)
Historic EBIAT for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to -$61.9 million.
- Regenxbio's EBIAT fell 393.31% to -$61.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$177.9 million, marking a year-over-year increase of 2549.78%. This contributed to the annual value of -$227.1 million for FY2024, which is 1381.13% up from last year.
- Per Regenxbio's latest filing, its EBIAT stood at -$61.9 million for Q3 2025, which was down 393.31% from -$70.9 million recorded in Q2 2025.
- Regenxbio's 5-year EBIAT high stood at $294.0 million for Q4 2021, and its period low was -$76.7 million during Q1 2022.
- Moreover, its 5-year median value for EBIAT was -$61.9 million (2023), whereas its average is -$40.5 million.
- The largest annual percentage gain for Regenxbio's EBIAT in the last 5 years was 73584.91% (2021), contrasted with its biggest fall of 76437.27% (2021).
- Regenxbio's EBIAT (Quarter) stood at $294.0 million in 2021, then tumbled by 120.38% to -$59.9 million in 2022, then decreased by 4.93% to -$62.9 million in 2023, then rose by 18.61% to -$51.2 million in 2024, then fell by 21.01% to -$61.9 million in 2025.
- Its EBIAT was -$61.9 million in Q3 2025, compared to -$70.9 million in Q2 2025 and $6.1 million in Q1 2025.